Nab-paclitaxel for the management of triple-negative metastatic breast cancer: a case study.
Nab-paclitaxel for the management of triple-negative metastatic breast cancer: a case study.
复制标题
用于管理三阴性转移性乳腺癌的NAB-甲酰胺：一个案例研究。
DOI：
10.1097/cad.0000000000000159
复制
发表时间：
2015-01
影响因子：
2.3
通讯作者：
De Angelis C
中科院分区：
文献类型：
--
作者：
Arpino G;De Placido S;De Angelis C
转移性乳腺癌（MBC）全身化疗的最佳顺序尚不清楚。我们报告了一位女性的病例，她在我们机构成功接受了纳米颗粒白蛋白结合 (nab) 紫杉醇治疗三阴性 MBC。 2008年11月，一名48岁女性因三阴性浸润性导管癌接受手术治疗，随后接受氟尿嘧啶/表阿霉素/环磷酰胺辅助化疗和放疗。手术后十六个月，她出现左胸壁转移瘤。该患者接受传统紫杉醇（每周 90mg/m2，共 4 周中的 3 周 [QW 3/4]）和贝伐单抗（每 2 周 10mg/kg [Q2W]）的联合治疗作为 MBC 的一线治疗（六个周期；2010 年 3 月至 9 月），并在转移部位取得了部分缓解。继续贝伐珠单抗单药治疗直至疾病进展（2011 年 4 月），出现单个锁骨下淋巴结转移和左胸壁病变尺寸增加。 2011年5月至12月，患者接受白蛋白结合型紫杉醇260mg/m²每3周（Q3W）作为二线治疗（11个周期）。三个周期后，左胸壁病灶和锁骨下淋巴结转移已检测不到，认为患者已获得完全缓解。治疗耐受性良好，没有明显毒性或需要减少剂量。鉴于我们的病例，我们在此回顾临床证据并讨论白蛋白结合型紫杉醇治疗三阴性 MBC 的潜在作用，三阴性 MBC 是一个典型的具有侵袭性疾病和有限治疗选择的亚组。
The optimal sequence of systemic chemotherapy in metastatic breast cancer (MBC) is unknown. We report the case of a woman who was successfully treated with nanoparticle albumin-bound (nab)-paclitaxel for triple negative MBC in our institution. In November 2008, a 48-year-old woman underwent surgical treatment for a triple negative invasive ductal breast cancer and subsequently received adjuvant chemotherapy with fluorouracil/epirubicin/cyclophosphamide and radiotherapy. Sixteen months after surgery, she presented with a left chest wall metastatasis. The patient received combination therapy with conventional paclitaxel (90mg/m² weekly for 3 out of 4 weeks [QW 3/4]) and bevacizumab (10mg/kg every 2 weeks [Q2W]) as first-line treatment for MBC (six cycles; March to September 2010) and achieved a partial response at the metastatic site. Bevacizumab monotherapy was continued until disease progression (April 2011) with the development of a single infraclavicular lymph node metastasis and an increase in the dimensions of the left chest wall lesion. From May to December 2011, the patient received nab-paclitaxel 260mg/m² every 3 weeks (Q3W) as second-line treatment (11 cycles). After three cycles, the left chest wall lesion and the infraclavicular lymph node metastasis were undetectable and the patient was considered to have achieved a complete response. Treatment was well tolerated with no significant toxicity or need for dose reduction. Given our case, here we review the clinical evidence and discuss the potential role of nab-paclitaxel for the treatment of triple negative MBC, a subgroup typically characterized as having aggressive disease and limited treatment options.